Galderma Holding SA has identified metabolites of CD-14547 acting as mammalian target of rapamycin (mTOR; FRAP1) inhibitors. As such, they are reported to be useful for the treatment of acne, atopic dermatitis, actinic keratosis and psoriasis.
RHOJ, a small GTPase, could hold the key to the survival of tumor cells during cancer treatments. When epithelial cells transformed into mesenchymal cells, the Rho-related GTP-binding protein RhoJ regulated their resistance to chemotherapy. The scientists observed this mechanism in mouse models of skin squamous cell carcinoma, but their results could go beyond just one type of cancer. When the team started its experiments, which were published March 23, 2023, in Nature, “I had never heard about RHOJ before,” the lead author Cédric Blanpain told BioWorld. Blanpain is the director of the Laboratory of Stem Cells and Cancer at the Université Libre de Bruxelles (ULB).
Takeda Pharmaceutical Co. Ltd.’s oral allosteric tyrosine kinase 2 inhibitor TAK-279 met primary and secondary endpoints in a phase IIb clinical trial in patients with moderate to severe plaque psoriasis, but analysts say it may be too little too late to make a big splash compared to competitors.
New and updated clinical data presented by biopharma firms at the American Academy of Dermatology annual meeting, including: Abbvie, Acelyrin, Arcutis, Concert, Connect, Galderma, Incyte, Inmagene, Leo, Nimbus, Regeneron, Sanofi, Sun, Takeda, UCB.
Takeda Pharmaceutical Co. Ltd.’s oral allosteric tyrosine kinase 2 inhibitor TAK-279 (formerly NDI-034858) met primary and secondary endpoints in a phase IIb clinical trial in patients with moderate to severe plaque psoriasis, but analysts say it may be too little too late to make a big splash compared to competitors.
3+2 Pharma LLC has divulged pyrazole-containing CREB-binding protein (CREBBP; CBP)/β-catenin (CTNNB1) interaction inhibitors reported to be useful for the treatment of fibrosis, cancer, aging, neurological, metabolic and dermatological disorders.
RSS
